RE:$4 DollarsWhile I AGREE that VP is undervalued, I think you overshot quite a bit with your MMJ comparison. MMJ has THREE pending MJ licenses in Canada, while VP has only one. To me, if they have three licenses, they should have roughly three times the value of VP, who has ONE pending license. VP DOES have some US business but there isn't much revenue from that and the US connection may be more of a hindrance than a help at this point.
I think better companies to compare VP to are late-stage applicants like LIB, ACG, and CHOO. By my numbers, LIB is pretty fairly valued as a late-stage applicant right now, but it currently has a market cap almost exactly 3 TIMES that of VP. I see both ACG and CHOO as undervalued, but even they each have a market cap about TWICE that of VP.
Just to get up to the RELATIVE value of the other late-stage applicants, I would say that VP needs to TRIPLE from here, so I say that a share price of $1.50 is fair for VP. Now, I am not saying that ANY of the late-stage applicants are correctly valued, but if they are all to have the same RELATIVE value, then VP is definitely behind the pack and needs to jump. By the way, this tripling of VP's market cap would ALSO bring it in line with MMJ, RELATIVELY.
BB
SizzlinSteaks wrote: That is where we should be if you compare VP to others like MMJ. MMJ currently has a market cap of $110 million. The same market cap puts us at $3.92 per share and I don't see much difference (except that MMJ is restricted to just Quebec). They are both emerging marijuana producers that have late stage applications with Health Canada. I think we will get there once investors begin to wake up and realize just how undervalued this is.